INNOVATION Council BETA INVESTOR DAY Nasdaq 7 March 2019 Stockholm-Sweeden

European

eic INNOVATION Council BETA INVESTOR DAY Nasdaq 7 March 2019 Stockholm-Sweeden

MORE INFORMATION ec.europa.eu/research/eic #EU_EIC @H2020SME

Horizon 2020

EIC Investor Day 1 Agenda

Date: 07 March, 2019 Venue: Tullvaktsvägen 15, 105 78 Stockholm, Sweden Host: Nasdaq

Registration 8:30 Tullvaktsvägen 15, 105 78 Stockholm, Sweden

Opening bell ceremony at NASDAQ 9:00 Opening keynote by Adam Kostyal Senior Vice President of Listing Services, Europe and Niclas Holmberg Managing Director of Global Listing Services at Nasdaq

European Commission/EASME 9:15 Welcome speech and introduction to the European Innovation Council (EIC) by Grzegorz Ambroziewicz, Acting Head of Unit European Commission EIC SME Instrument

Discussion panel session 1– Topic: Going public, reaching the grail or crazy choice? Joakim Falkner, Head of ECM Nordic at Baker McKenzie 9:30 Pieter van Mejden, Vator Securities Ann-Christin Malmborg Hager, CEO SenzaGen

10:30 Networking coffee-break

Discussion panel session 2 – Topic: How to go public? 11:00 Erik Gatenholm, CEO Cellink Henrik Carlman, Portfolio Manager Swedbank

12:00 Networking lunch-break

Cobiro Datapole Pitching session 1 13:00 Echandia Marine (Parallel one2one meetings) Genomic Expression HappyOrNot

EIC SME instrument portfolio performance and business acceleration services 14:00 Diana Rucinschi – Project Officer EIC SME Instrument

Ilya Pharma Lipum Pitching session 2 14:15 UtopiaAI by NSI (Parallel one2one meetings) Nuritas Respinor

15:15 Networking coffee-break

Submer Technologies Symcel Sverige Pitching session 3 15:45 Think Silicon (Parallel one2one meetings) Truelinked Wheel Me

16:45 Award ceremony Award for the winner of each pitching session

17:00 Wrap-up

17:30 End what is the 2 EIC pilot? The European Innovation Council pilot supports top-class innovators, entrepreneurs, small companies and scientists with bright ideas and the ambition to scale up internationally. It brings together the parts of Horizon 2020 that provide funding, advice and networking opportunities for those at cutting edge of innovation.

The EIC pilot is an initiative of the European Commission that proposes substantial funding and competitive oﬀ erings for innovators regarding access to ﬁ nance, coaching, and other means of support. The EIC pilot consists of four support programmes including the SME Instrument, Fast- Track to Innovation (FTI), Future and Emerging Technologies Open (FET-Open), and the Horizon Prizes.

4 55k 400 4000 €2b years of the applications coaches deployed SMEs supported in funding programmes some of our measures of 3 success

Accelerated growth of SMEs Access to Capital

“This prestigious grant gave us a valuable A year down the line, funded companies recognition that played a major role in experience on average: our IPO. It strengthened our credibility in front of investors and customers and increase in turn-over helped us run a number of projects in 118% order to reach full scale production.” increase in Anders Lundström, CEO Svenska Aerogel 158% employment Funding € 1 million *EIC SME Instrument Impact Report 2018

Sector diversifi cation Industry sectors where funded companies attract more investments than average 6 4 2 m €

developer publisher construction home robotics analytics marketing tools directory sports tools

Average investment in EIC SME Instrument funded companies Average investment in the industry company 4 Index

Cobiro. ��6 Datapole ��7 Echandia Marine. ��8 Genomic Expression. ��9 Happyornot. �� 10 Ilya Pharma. �� 11 Lipum �� 12 Nuritas. �� 13 Respinor �� 14 Submer Technologies. �� 15 Symcel Sverige. �� 16 Think Silicon. �� 17 Truelinked. �� 18 UtopiaAI by NSI. �� 19 Wheel.me. �� 20 eic BETA EUROPEAN INNOVATION COUNCIL

Cobiro Denmark | www.cobiro.com

Bo Krogsgaard Anders Ibsen CEO CCO

Cobiro is an AI-powered automation platform for Google Ads. By using NLP and ML we are capable of analyzing web pages and generating very accurate keywords and setting it up in a professional grade structure. Cobiro also optimizes the ROI of a campaign by bidding very accurately in the auctioning model of Google Ads. We serve more than 30,000 customers from 189 countries and are one of the largest partners to Google globally. Cobiro has raised $9.6, employs 46 people and are ramping up revenue very rapidly.

Unique Selling Point You do not need a phd to set up and outperform educated online marketing specialists.

Key Clients We serve SMB customers from 189 countries.

Investor Type Venture capitalists, Business angels, Strategic investors, Corporate venture capital, Family offi ces/High Networth individuals, Corporate investors

Target Investment Ticket > 10,000,000€

6 EUROPEAN INNOVATION COUNCIL eic BETA

Datapole France | www.datapole.com

Frédéric Gagnaire CEO

DATAPOLE is an editor of so ware Solution dedicated to the optimization of human and material resources. The Solutions developed by DATAPOLE rely on powerful algorithms of artifi cial intelligence. These Solutions help to better understand and anticipate the fl uctuations of an activity in order to size the resources close to the real need of the users. From master planifi cation to dynamic daily scheduling, our Solutions support operations to achieve their goals in terms of customer satisfaction, cost reduction and environmental footprint.

Unique Selling Point Key Clients Since 2010, with the support of the CNRS (French Engie, Vinci, Dalkia, Cofely, Ferrovial, Diehl Metering, National Center for Scientifi c Research), we developed Celsa, Group, Atos, Thomas Watt, RATP. our own technology: a models factory with industrialize the work of Data scientists. Investor Type By design this technology guaranties we select for our Venture capitalists, Corporate venture capital, clients the best statistical method to optimize their day Corporate investors, Family offi ces. to day operations for each level of their organization. This technology, PrediSmart®, is a unique, innovative, Target Investment Ticket SaaS Platform which gathers Machine Learning tools, 3,000,000€ - 5,000,000€ Predictive Analytics tools, Optimization tools, Semantic Analysis Tools, Data Cleansing tools and Big Data technologies so we can help private companies and public organizations get out the best of their data. However, data and technologies do not create value. This is their business application that creates value. This is the reason why we built the ability to easely developed specifi c modules dedicated to operational people in order to match their expectations and fi t with their specifi c working environment. This ability to is a key strength among AI-tools providers.

7 eic BETA EUROPEAN INNOVATION COUNCIL

Echandia Marine Sweden | www.echandiamarine.com

Hans Thornell Chairman

Echandia Marine designs and delivers electric drivelines for ferries and vessels. In the EU-funded project “Green Fast Ferries” we have developed the driveline for BB Green – the world’s fastest battery driven passenger ferry. The chosen battery system is based on Toshiba’s LTO battery modules which have long life and can stand fast charging. Echandia has become Toshibas distributor in the maritime sector.

Unique Selling Point 1. The passenger ferry uses 40 % less energy than similar sized conventional high-speed ferries (80 - 150 passengers) and the operational costs are considerably lower.

2. The battery system based on Lithium-Titanium-Oxide (LTO) can take faster charging and has longer life-time than the dominating type of marine battery systems.

Key Clients Ship-owners/operators in cities or in archipelagos Batteries are sold to shipyards or system integrators. Charging stations will be sold to power suppliers.

Investor Type Strategic investors

Target Investment Ticket 5,000,000€ - 10,000,000€

8 EUROPEAN INNOVATION COUNCIL eic BETA

Genomic Expression Denmark | www.genomicexpression.com

Gitte Pedersen CEO & Co-founder

OneRNA™ can save lives and making healthcare delivery more eﬀ ective by sequencing RNA and linking actionable over or under expressed RNA’s to therapies and clinical trials.

We raised $8M to clinically validate OneRNA™ in 4 cancers focusing on women’s cancer ﬁ rst. We are raising a series A for regulatory approvals. That will bring our OneRNA™ platform from a $1B tool market into the $20B diagnostic market. We are currently generating revenue from our collaborations, closed deal value $1M.

Unique Selling Point Key Clients Breast, ovarian and other cancers are not “driven” by We developed a Marketing and Sales strategy where mutations and thus don’t benefi t from DNA sequencing were are leveraging 3rd party sales force as well as our to the extend that other high mutation frequency cancers own to get in front of large hospital systems, doctors does. When we compare DNA panels of 275 genes and integrated payer/provider systems. Pharma is from e.g. Foundation Medicine ($FMI), they identify demonstrating an increasing interest in partnering 1(One!) marker in 80% of the patients and therefore with diagnostic companies to identify patients that can they theoretically improve outcome in 16% of patients. benefi t from treatment with their drugs. The largest deal in this space is between Pfi zer and Exact science where OneRNA™ does not use panels, sequences +20,000 Pfi zer is leveraging their sales force and committing RNA markers and identifies 5 markers in 100% of $40M to market Exact test to doctors. the patients. That means that OneRNA™ has the potential to improve outcome in most patients. Investor Type Venture capitalists, Private equity, Strategic investors, OneRNA™ method could be launched as a diagnostic Corporate venture capital, Family offi ces/High Networth product in approximately 12 month. The benefi t to the individuals, Corporate investors patients is signifi cant and can be achieved within 12 months, not ten years which is the typical timeframe Target Investment Ticket for drug development. > 10,000,000€

9 eic BETA EUROPEAN INNOVATION COUNCIL

HappyOrNot Finland | www.happy-or-not.com

Heikki Väänänen CEO

HappyOrNot® is the global leader in real time customer and employee satisfaction measurement and analysis, in moment and on location. The globally-recognized and trusted 4 Smileys capture the satisfaction levels of customers and employees in just seconds and the Reporting Service helps our clients track and manage their performance by transforming the feedback into data analytics that are actionable and support knowledge based strategic decision-making. Our innovative service help our clients to improve and optimize their customer experience, relationships, and employee engagement. We serve over 4,000 companies across 120 countries and have collected and reported more than one billion experiences.

Unique Selling Point HappyOrNot has the most comprehensive product The HappyOrNot solution is approachable for everyone portfolio on the market, the biggest amount of data (age, gender, any demographics) and analyzes and collected and the largest customer network by account reports experiences in the moment and on location size & feedback. We are growing faster than ever! without needing a previous engagement, therefore enabling our clients to make immediate corrective Key Clients actions. We help discover the root cause of customer We serve a broad range of business industries, focusing dissatisfaction, transform the feedback into actionable on retail, transportation, services, entertainment and insights on operational, mid-management and C-level healthcare. Our key markets are the US, Nordics, and enable faster and more effi cient than ever, A/B France, Germany and the UK, however we operate testing in the real world. Our clients benefi t from the globally. We are constantly attracting more enterprise insight base and benchmark data from over 1billion level businesses. A few of the businesses that run on customer experiences collected and reported to date. HappyOrNot are Walmart, Carrefour, Amazon, Boots, Heathrow airport, Levi’s stadium, United States Postal, Our complete solution Sodexo services and many more. • Uncovers pain points (e.g. certain hour or day in retail store) Investor Type • Improves experiences Venture Capital, Corporate Venture Capital • Increases loyalty and referrals • Enhances brand reputation Target Investment Ticket • Grows revenue 10.000.000€ - 20.000.000€

10 EUROPEAN INNOVATION COUNCIL eic BETA

Ilya Pharma Sweden | www.ilyapharma.se

Evelina Vagesjo CEO

Ilya Pharma develops next-generation biologics for treatment of wounds in skin and mucosa. The technology is a new and a very cost-eff ective technology for local delivery of biological drugs. The fi rst indication targeted is treatment large and chronic wounds with the next milestone is a phase I clinical trial in fi rst part of 2019 for validation of the lead drug candidate ILP100. The development plan is validated by the relevant regulatory bodies and the company have received numerous award for breaking new ground in wound care and biologics.

Unique Selling Point Key Clients The customer benefi ts are acceleration of healing of Customers are any company or research group modifying large and chronic wounds with reduced use of antibiotics, biological systems (protein, antibodies, bacteria, crops, limited spread of antibiotic resistance and signifi cantly virus, etc) to develop new applications. About 50% of reduced health care related costs. the market is in the US, 20% in Asia and 30% in Europe.

The innovation is a pharmaceutical drug candidate Investor Type based on lactic acid bacteria that are engineered to Venture capitalists, Strategic investors, Corporate express a human protein that is well described in tissue venture capital, Family offi ces/High Networth individuals, regeneration. The drug candidates are both a novel drug Corporate investors. delivery system and each bacteria is also a separate API. Using this on site delivery system as compared to Target Investment Ticket application of recombinant proteins to wounds, it is a > 10,000,000€ very cost effi cient technology to deliver biologics and it also overcomes the rapid degradation of proteins in wounds by the continuous secretion. The technology inherently also provide competitive and direct forces to limit growth of other wound bacteria. Manufacturing have been scaled material produced GMP. The compounds are classifi ed as advanced therapy medicinal products (ATMPs) and regulatory and clinical feasibility is verifi ed.

11 eic BETA EUROPEAN INNOVATION COUNCIL

Lipum Sweden | www.lipum.se

Einar Pontén CEO

Lipum AB is a biopharmaceutical company that aims for better quality of life for the millions suff ering from chronic infl ammatory diseases. We are dedicated to develop a novel, safe and eff ective drug that will fulfi ll an important unmet medical need. A non-clinical proof of concept has been established and a humanized monoclonal antibody developed.

Unique Selling Point had been treated with one of these biological drugs Lipum has identified a novel target molecule for for at least 6 months, one third had discontinued their treatment of chronic infl ammatory diseases. treatment aﬅ er 1 year, and nearly 60% aﬅ er 3 years. Pre-clinical proof of concept in well established animal The most common reason was lack of effi cacy (36%). models. Blocking the target molecule constitutes a novel New innovative drugs providing a novel mode of action mode of action with less expected side-eff ects on the is needed. Lipum aims to fi ll this gap and has identifi ed immune system. a novel target for treatment of chronic infl ammatory diseases. The target is a protein denoted bile salt- Key Clients stimulated lipase (BSSL). We have shown a signifi cant Treatment of severe juvenile idiopathic arthritis (JIA) correlation between BSSL concentration in plasma in children and rheumatoid arthritis (RA) in adults and disease activity score 28 (DAS28) in RA, JIA and typically includes one biological drug targeting the psoriatic arthritis patients. Lipum´s therapeutic approach pro-infl ammatory cytokine TNF-α, e.g. adalimumab is to develop an antibody that blocks the function of (Humira), etanercept (Enbrel) or infl iximab (Remicade). BSSL thereby inhibiting the inflammatory process. The total market value of these drugs in RA is >20B€. Despite the use of anti-TNF-α agents, and more Investor Type recently the JAK-inhibitor tofacitinib and also other Venture capitalists, Private equity, Business angels, anti-infl ammatory drugs there is still a high unmet Strategic investors, Corporate venture capital, Family medical need. A signifi cant number of patients do not offi ces/High Networth individuals, Corporate investors. respond to, or only respond transiently to TNF-α inhibitor drugs. A report from North America (Corrona Database) Target Investment Ticket 12 revealed that out of more than 6 000 patients that 15.000.000€ (during year 2020) EUROPEAN INNOVATION COUNCIL eic BETA

Nuritas Ireland | www.nuritas.com

G r e g S t a ff o r d CFO

Nuritas is the ﬁ rst company in the world to demonstrate that AI can accelerate the discovery of a healthcare product from concept to market in less than 3 years. Nuritas is a discovery platform for active peptides that can prevent or treat disease with industry leading speed and accuracy. The company is changing the landscape of drug discovery by identifying novel peptides using a proprietary artiﬁ cial intelligence (AI) platform, with in-silico predictions validated by their in-house laboratory and multidisciplinary team of scientists. Nuritas engages in collaborative partnerships in the pharmaceutical and consumer goods industries to conduct peptide discovery that is faster, more accurate, and less expensive than traditional drug discovery.

Unique Selling Point Investor Type Nuritas is a discovery platform for active peptides Venture capitalists, Private equity, Strategic investors, that can prevent or treat disease with industry Corporate venture capital. leading speed and accuracy. It is successfully doing so currently in collaboration with a number of industry Target Investment Ticket leading multinationals. One part of a multi facotred > 10,000,000€ collaboration with BASF has resulted in the launch of the world‘s fi rst healthcare product discovered using AI . The multi-award winning company is changing the landscape of drug discovery by identifying novel peptides using a proprietary artifi cial intelligence (AI) platform, with in-silico predictions validated by their in-house laboratory and multidisciplinary team of scientists.

Key Clients We deal with Multinational companies across our industries of focus. The customers whom we can disclose publicly are BASF and Nestlé. In November 2018 we launched the world‘s fi rst Healthcare product discovered and validated using Artifi cial Intelligence.

13 eic BETA EUROPEAN INNOVATION COUNCIL

Respinor Norway | www.respinor.com

Nicolay Berard-Andersen CEO

Respinor is a privately-owned medical device company, founded in Oslo, 2015. We have developed an objective measure of breathing for critically ill patients within intensive care. The technology provides practitioners with precise, continuous and real-time information of diaphragm function, our main breathing muscle, to increase the quality of care and reducing costs. RESPINOR’s technology is the winner of Horizon 2020 both in phase I and II. We are addressing an unmet medical need, because every breath counts.

Unique Selling Point Key Clients Providing clear customer benefi ts made RESPINOR’s Initially we aim at bringing our technology to the fi eld technology a winner of Horizon 2020 funding. To of MV with 4,5M patients in EU/USA per year, and continuously monitor the diaphragm, our main breathing subsequently to broaden the platform to address muscle, will enable physicians to optimize treatment multiple uses within respiratory and intensive care (IC), for mechanically ventilated (MV) patients. which is estimated to 42M patients in EU/USA per year. RESPINOR DXT is changing respiratory health by providing First, we plan to test our value proposition in Norway. an objective measurement of diaphragm activity for Second, we launch in major EU markets (Germany and faster, timely decisions in respiratory care, better patient France) to demonstrate success before further market quality of life and resulting in lower healthcare costs. expansion through external global partners. Non-invasive: • Long term non invasive monitoring of Respiratory Investor Type Rate and volume Venture capitalists, Business angels, Strategic investors, • No discomfort or infection risk for patients Family offi ces/High Net worth individuals. • Continuous monitoring: • Reliable data compared to present handheld Target Investment Ticket ultrasound imaging 5,000,000€ - 10,000,000€ • Disposable sensor kit Easy to use: • Minimum training required • Simple user interface • No need for operator presence 14 EUROPEAN INNOVATION COUNCIL eic BETA

Submer Technologies Spain | www.submer.com

Pol Valls Soler Co-founder

Datacenters and cloud providers consume 6% of the global electricity (more than India) and generate 4% of the global CO2 emissions (more than 2 times commercial air travel). Submer develops a highly eﬃ cient, eco-friendly immersion cooling solution for any kind of IT HW/Computing that saves 50% of the electricity and 85% of the physical space for datacenters, cloud providers, AI and blockchain. Also perfect for Edge Computing and IoT, it can be placed anywhere, even directly outdoors without expensive buildings. Renowned institutions like the European Commission H2020 and venture capital back the company and its innovative technology is being used by very important institutions like the CERN Large Hadron Collider, Airbus, Baidu, Microso ...

Unique Selling Point • High Frequency Trading Submer develops the SmartPod, a highly efficient • Smart Cities immersion cooling solution that increases computing • IoT density by 85% (saving this amount of real estate), • Defense saves 50% of the electricity and reduces substantially • Oil & gas Platforms building costs for data centers, cloud providers, IoT and • etc. blockchain/AI infrastructure. It is also the perfect edge computing solution as it can be placed anywhere (even Investor Type outdoors or buried under the ﬂ oor). Venture capitalists, Strategic investors, Corporate venture capital, Family offi ces/High Networth individuals. Key Clients • High Performance Computing Target Investment Ticket • Hyper-scale Cloud Providers 5,000,000€ - 10,000,000€ • Corporate Datacenters • Colocation • Research Datacenters • Government institutions • Hosting • Blockchain (including cryptocurrency miners) • Telcos • Banking • Edge computing applications 15 eic BETA EUROPEAN INNOVATION COUNCIL

Symcel Sverige Sweden | www.symcel.se

Jesper Ericsson CEO

Symcel develops an analytical instrument that can reduce the global threat of antibiotic resistance. We enable researchers to measure the killing eﬀ ects of bacteria with high sensitivity by directly measuring one of the key fundamentals of life - metabolism. Founded by leading academic authorities and driven by an experienced team of entrepreneurial scientists and a professional board with some of Sweden’s most successful life science executives.

Unique Selling Point Investor Type Real-time treatment eff ects (death) in virtually any Venture capitalists, Business angels, Corporate venture biological system and format. capital, Family offi ces/High Networth individuals

Quantification of biofilm formation or inhibition of Target Investment Ticket growth in human-like environments . 5,000,000€ - 10,000,000€

Rapid treatment eff ects of combinations of antibiotics against multidrug-resistant bacteria.

Label-free cell based assay for 2D, 3D and complex models that makes it possible to see drug eff ects where other technologies are blind.

Key Clients Microbiology researchers and governmental organizations that are developing improved diagnostics and/or treatments of severe infectious diseases or analyzing eff ects of antibiotic resistance in relation to new medical devices, implants etc. Pharmaceutical researchers working with drug development of novel compounds that either exert a cell killing eff ect or have a specifi c 16 eff ect on metabolism. EUROPEAN INNOVATION COUNCIL eic BETA

Think Silicon Greece | www.think-silicon.com

George Sidiropoulos CEO

Think Silicon is developing and licensing the most power eﬃ cient graphics technology in the world. Think Silicon is specialized in designing the only ultra low-power and low-cost Graphics Processing Unit (GPU) bringing High Quality Graphics on any smart IoT display device. The latest development of the company is a RISC-V ISA based GPU targeting the Artiﬁ cial Intelligence (AI) market for machine learning vision applications on the IoT/Edge end-nodes.

Unique Selling Point Investor Type NEMA® is the only graphics solution for Microcontrollers Venture Capital, Corporate Venture Capital (MCU) providing smart-phone like user experience, while extending battery life, keeping the cost within the MCU Target Investment Ticket envelop and shortening the time-to-market. The above 2,000,000€ - 5,000,000€ is achievable due to the NEMA®’s patent protected technology which provides ultra-low power consumption and low cost by decreasing silicon area and memory requirements while shortening the development time by using the NEMA® Soﬅ ware Development Kit (SDK).

Key Clients Think Silicon’s customer base includes semiconductor companies, designing and fabricating chips, like Microchip Corp, Dialog Semiconductor, Sequans Communications, Lattice Semiconductor. Signed IP licenses with initial Fee and following royalty stream generated by sales- volume per unit, represents the core business model.

17 eic BETA EUROPEAN INNOVATION COUNCIL

UtopiaAI by NSI Italy | www.utopiathesoﬅ ware.it

Gianluca Velez Stefano Borghi Andrea Garganico CEO Project Coordinator Product Owner

NSI is a digital transformation company. Since 2002, we have been helping companies to redesign their business models and grow with customized IT solutions and digital products. UTOPIAAI is our cloud solution so ware that provides the necessary tools to comply with the General Data Protection regulation (GDPR). We want grow, strength and consolidate trust that European citizens have towards companies that manage their personal data. UTOPIAAI provides those companies all the tools by which demonstrate compliance towards the supervisory authority and makes personal data processing clear, transparent and secure to citizens.

Unique Selling Point Investor Type UTOPIAAI is the fi rst world-wide cloud soﬅ ware solution Venture capitalists, Private equity, Strategic investors, that provides all the tools and services to achieve Corporate venture capital, Corporate investors. and prove General Data Protection Regulation (GDPR) compliance for privacy management. It integrates MIA a Target Investment Ticket breakthrough multilingual artifi cial intelligence assistant 1,000,000 - 3,000,000€ that guides companies towards compliance, suggests privacy best practices, educates people involved, and automatically checks the level of conformity.

Key Clients UTOPIAAI is specifi cally designed for small, medium, micro enterprises and NGOs that are postponing the GDPR compliance activities due to lack of technical skills, budget and privacy culture.

UTOPIAAI also simplify job of Data Protection Offi cers (DPOs) and privacy consultants who are managing many enterprises at the same time.

18 EUROPEAN INNOVATION COUNCIL eic BETA

Truelinked Denmark | www.truelinked.com

Sune Hjerrild Jan Pilgaard Carlsen CEO and Co-founder COO and Co-founder

Truelinked is an award-winning Danish tech start-up, founded in 2013 and now the world’s leading digital community for opera and classical music, aiming to connect arts organisations, artists, agents and audience. Truelinked changes the way the industry communicates and the way talent is discovered, in turn drastically improving workﬂ ows and the experience of all industry stakeholders. The company’s business model taps into the €20billion per annum freelance market. In addition, the much larger audience economy, estimated to be worth signiﬁ cantly more, is within our sight. Truelinked is also destined to evolve into other performing arts verticals once we have a proven model for the current industry.

Unique Selling Point Key Clients Agents: In a place where hundreds of arts organizations Our clients are the four A‘s: the Arts organizations, are looking daily, agents get the best channel to the Artists, The Agents and the Audience. Our revenue bookings, talent discovery, career insight data, and streams wary from direct bookings to subscriptions visibility for their artists. from selling data, tools, and services.“

Arts organizations: Arts organizations get a complete Investor Type view of the talent pool, valid performance data, and Venture capitalists, Private equity, Strategic investors, a network to support their decisions in a seamless Corporate venture capital workﬂ ow empowering their processes. Target Investment Ticket Artists: In a place where hundreds of arts organizations 10.000.000€ - 20.000.000€ are looking daily, artists get visibility in order to gain job opportunities, data to guide and validate their choices and a network to endorse their talent.

Audience: In one platform involving all stakeholders of the art form the audience can access high-value content information and interaction brought to them directly from their favorite venue or artists.

19 eic BETA EUROPEAN INNOVATION COUNCIL

wheel.me Norway | www.wheel.me

Atle Timenes Morten Kompen CEO CFO

Driven by the vision of Forever Changing Indoor Mobility, wheel.me aims to become a preferred international platform for indoor mobility and materials handling by 2022. In essence, what is being attempted with self-driving cars outdoors, wheel.me will perform indoors through small and cost-eﬀ ective embedded robots (“Smart Wheels”).

Unique Selling Point Key Clients wheel.me will let anyone – young or old, strong or Paid pilots are currently run with players in multiple Smart weak – move objects (furniture, heavy goods & pallets, Building verticals (B2B): Healthcare, airports, factory medical beds & equipment – and even full-size walls) operations, logistics/supply chain, and Smart Living/ fi tted with Smart Wheels to their desired position by voice combo buildings. A distribution agreement is signed activation or other wireless communication (sticker, app with Häfele, the world’s largest supplier of furniture or back-end). The innovation transforms anything into a fi ttings. Agreements are also signed with two major robotic device with minimal eff ort without the need to system integrators to promote wheel.me’s solutions. change the design or form factor. Unique Selling Points: Investor Type • Making any object “smart” and set for autonomous Venture capitalists, Strategic investors, Corporate movement venture capital, Family offi ces/High Networth individuals, • Provide asset tracking with autonomous delivery Corporate investors • Simplifying everyday life by reducing or removing manual work Target Investment Ticket • Orders of magnitude lower hardware cost than 3,000,000 - 5,000,000€ existing automation solutions

20 Business Acceleration Services 5 EIC pilot

The European Innovation Council pilot focusses on continuous improvement, networking, learning opportunities and facilitating access to business partners and investors. Being part of the programme offers you a life-long privileged access to our user-driven business acceleration services, customized to your needs.

How to Participate?

You can register or apply for all the events via the SME Dashboard. We also invite you to join the new EIC Community platform (community-smei.easme-web.eu), where you will find additional information and discussion groups related to EIC pilot events, coaching and training services.

In the EIC Community you will also find a smart matchmaking tool designed to connect investors and companies funded by the EIC pilot – ScaleUp EU.

Upcoming Events:

19.03.2019 - Corporate Day - Munich, Germany MAN Truck&Bus

26.03.2019 - Corporate Day - Lisbon, Portugal EDP and Partners

03-04.04.2019 - Corporate Day - Brussels, Belgium Procter&Gamble and Partners

04.04.2019 - Investor Day - Brussels, Belgium Women in Tech

13-14.04.2019 - Corporate Day - Paris, France Orange

24-25.04.2019 - Corporate Day - Hamburg, Germany Comdirect and Partners

13-14.05.2019 - Corporate Day - Madrid, Spain Telefonica & BBVA

15.05.2019 - Investor Day - Paris, France Euronext

23.05.2019 - Corporate Day - Paris, France Saint-Gobain your 6 Notes

This EIC pilot Business Acceleration Services event has been organised with the support of Nasdaq.

About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with conﬁ dence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s ﬁ rst electronic stock market, its technology powers more than 100 marketplaces in 50 countries. Nasdaq is home to over 4,000 total listings with a market value of approximately $12 trillion. To learn more, visit business.nasdaq.com.

Join the EIC Community platform community-smei.easme-web.eu

Check out the EIC SME Instrument Impact Report 2018 europa.eu/!bd84RD

More information on the EIC pilot Business Acceleration Services [email protected] [email protected]

@H2020SME #EU_eic